HomeThemesTypesDBAbout
Showing: ◈ medicine×
The United Kingdom has passed the point of no return. It has less than six months to reach a new trade deal with the European Union or risk heaping more pressure on companies that are already laying off tens of thousands of workers because of the coronavirus pandemic.
UK foreign secretary has said EU invite for Covid-19 scheme was sent to old email address.
Everyone is fishing in the same pond. Stocks built up in readiness for Brexit are having to be replenished. If another pandemic strikes, we’ll hardly be in the best position to get through it.
'Trade campaigners have welcomed the release of leaked papers detailing trade talks between the Trump administration and British government officials, which show the US government pushing Britain into as hard a Brexit as possible because they see this as the best way of benefitting the US economy. This comes at the expense of standards, protections and livelihoods in Britain.'
'The Brexiters have no more idea in private than they do in public about what they are doing. Predictions based upon their concealed intent project on to them a competence they simply don’t possess.'
Demands for prime minister to reveal if dangers listed in ‘no-deal readiness report’ last autumn are still real – and whether they have grown because of pandemic.
The United Kingdom will delay the introduction of border checks on imports from the European Union by as much as six months in a bid to avoid piling on the pain for British business and choking off vital food supplies.
A no-deal Brexit later this year during winter and amid coronavirus would be ‘a vicious, and avoidable, combination of risks’ says Health Foundation.
The UK has been warned by the pharmaceutical industry that some stockpiles of medical supplies have been "used up entirely" by the virus.
Pharmaceutical industry says restocking before December looking impossible.
A no-deal Brexit could jeopardise the UK’s access to medicine just as a second wave of coronavirus could hit.
A Mirror probe reveals fears medicine shortages will put thousands of lives at risk if Britain crashes out of the EU.
With the NHS under such exceptional pressure during the coronavirus crisis, it’s easy to overlook the fact that the UK’s Brexit transition period ends on December 31. Mark Dayan takes a closer look at how these two challenges for the health service might collide, and says there is a case to err on the side of caution.
Experts warn that European Medicines Agency membership would have had advantages.
President will put US firms first in UK trade talks, says Kim Darroch
The paper, commissioned by the Scottish Government, identified 137 potential impacts.
A review of evidence about opportunities, challenges and risks to the North East economy and its key sectors with recommendations for action.
The UK must ensure that it retains access to the Single Market, has an open trading regime and maintains a stable regulatory framework with the European Union to minimise the impact of Brexit on the North East economy. This is the key conclusion of ‘Leaving the European Union’, a report by a powerful regional economic group says today.
Ministers will relax rules around clinical trials and streamline the approval of new medicines in a bid to maintain Britain’s competitiveness following Brexit.
When President Donald Trump arrived in the United Kingdom this week, he landed bang in the middle of a huge political fight about the country's National Health Service.
Brian Toohey, of the Pharmaceutical Research and Manufacturers of America trade group, spearheads PhRMA and recently told of the US drugs industry's predatory intentions.
This video from January is US Pharma industry lobby telling US trade negotiators that US-UK trade deal is “an important opportunity” to deal with “artificially depressed prices” in UK - “dictated” via our “primary payer” system